ScinoPharm Taiwan Ltd
TWSE:1789
Intrinsic Value
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. [ Read More ]
The intrinsic value of one
ScinoPharm Taiwan Ltd
stock under the Base Case scenario is
15.26
TWD.
Compared to the current market price of 28.4 TWD,
ScinoPharm Taiwan Ltd
is
Overvalued by 46%.
ScinoPharm Taiwan Ltd's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
ScinoPharm Taiwan Ltd or that its price is influenced by factors unrelated to fundamentals.
ScinoPharm Taiwan Ltd's market capitalization is 22.5B TWD.
ScinoPharm Taiwan Ltd stock price is 28.4 TWD.
ScinoPharm Taiwan Ltd stock (15.26 TWD) is 46% less than its price (28.4 TWD).
ScinoPharm Taiwan Ltd stock (11.88 TWD) is 58% less than its price (28.4 TWD). Open DCF Valuation
ScinoPharm Taiwan Ltd stock (18.63 TWD) is 34% less than its price (28.4 TWD). Open Relative Valuation
ScinoPharm Taiwan Ltd has downside potential of 5% compared to the average analyst price target.
Open Wall St Estimates
ScinoPharm Taiwan Ltd's ROE (Return on Equity) has decreased in the last 3 years from 3% to 3%.
ScinoPharm Taiwan Ltd's Revenue has been growing by 1% per year for the last 3 years.
ScinoPharm Taiwan Ltd has positive Operating Income for the last twelve months.
ScinoPharm Taiwan Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 5% to 3%.
ScinoPharm Taiwan Ltd has positive Net Income for the last twelve months.
ScinoPharm Taiwan Ltd's Revenue has dropped by 2% over the past 12 months.
ScinoPharm Taiwan Ltd's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 3%.
ScinoPharm Taiwan Ltd's ROE (Return on Equity) for the past 12 months is very low and is equal to 3%.
ScinoPharm Taiwan Ltd has a very low three-year average ROE (Return on Equity): 3%. The company is not efficient at transforming stockholders' equity into net income.
ScinoPharm Taiwan Ltd has a very low three-year average ROIC (Return on Invested Capital): 3%. The company is not efficient at using invested capital to generate operating income.
ScinoPharm Taiwan Ltd has negative Free Cash Flow for the last twelve months.
ScinoPharm Taiwan Ltd has positive Gross Profit for the last twelve months.
ScinoPharm Taiwan Ltd's D/E (Debt to Equity) is very low and is equal to 0.06.
ScinoPharm Taiwan Ltd's short-term assets (6B TWD) exceed its short-term liabilties (729m TWD).
ScinoPharm Taiwan Ltd's long-term assets (12B TWD) exceed its long-term liabilties (1B TWD).
ScinoPharm Taiwan Ltd has negative Net Debt. This means that the company has more cash and short-term investments (4B TWD) than debt (602m TWD).
ScinoPharm Taiwan Ltd's Altman Z-Score is very high and is equal to 9.93.
ScinoPharm Taiwan Ltd earns more than enough operating income (314m TWD) to safely cover interest payments on its debt (9m TWD).
Valuation Backtest
ScinoPharm Taiwan Ltd
Run backtest to discover the historical profit from buying and selling
ScinoPharm Taiwan Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
ScinoPharm Taiwan Ltd
Balance Sheet Decomposition
ScinoPharm Taiwan Ltd
| Current Assets | 6.4B |
| Cash & Short-Term Investments | 3.9B |
| Receivables | 813.5m |
| Other Current Assets | 1.6B |
| Non-Current Assets | 5.3B |
| Long-Term Investments | 100.9m |
| PP&E | 4.6B |
| Intangibles | 19.2m |
| Other Non-Current Assets | 643.3m |
| Current Liabilities | 729.5m |
| Accounts Payable | 102.5m |
| Accrued Liabilities | 139.8m |
| Short-Term Debt | 32.1m |
| Other Current Liabilities | 455.1m |
| Non-Current Liabilities | 627.7m |
| Long-Term Debt | 570.2m |
| Other Non-Current Liabilities | 57.5m |
Earnings Waterfall
ScinoPharm Taiwan Ltd
|
Revenue
|
3.2B
TWD
|
|
Cost of Revenue
|
-2B
TWD
|
|
Gross Profit
|
1.2B
TWD
|
|
Operating Expenses
|
-901.5m
TWD
|
|
Operating Income
|
314.5m
TWD
|
|
Other Expenses
|
-27.4m
TWD
|
|
Net Income
|
287.1m
TWD
|
Free Cash Flow Analysis
ScinoPharm Taiwan Ltd
Profitability Score
Profitability Due Diligence
ScinoPharm Taiwan Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
ScinoPharm Taiwan Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
ScinoPharm Taiwan Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
ScinoPharm Taiwan Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
ScinoPharm Taiwan Ltd
According to Wall Street analysts, the average 1-year price target for
ScinoPharm Taiwan Ltd
is 27 TWD
.
Shareholder Return
Price
ScinoPharm Taiwan Ltd
| Average Annual Return | 2.03% |
| Standard Deviation of Annual Returns | 10.57% |
| Max Drawdown | -41% |
| Market Capitalization | 22.5B TWD |
| Shares Outstanding | 790 962 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
ScinoPharm Taiwan Ltd
Country
Industry
Market Cap
Dividend Yield
Description
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
Contact
IPO
Employees
Officers
The intrinsic value of one
ScinoPharm Taiwan Ltd
stock under the Base Case scenario is
15.26
TWD.
Compared to the current market price of 28.4 TWD,
ScinoPharm Taiwan Ltd
is
Overvalued by 46%.
You don't have any saved screeners yet
